Tag: LivaNova

LivaNova Launches International Pivotal Study Evaluating Use of Autonomic Regulation Therapy for Heart Failure

LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced the first successful implantation of the VITARIA® System in a patient enrolled in the Autonomic Regulation Therapy to Enhance Myocardial Function and Reduce Progression of Heart Failure With Reduced Ejection Fraction (ANTHEM-HFrEF) Pivotal Study. The study is an international, multi-center, randomized trial to evaluate the VITARIA System for the […]

LivaNova Welcomes NICE Interventional Procedures Guidance on Sutureless Aortic Valve Replacement

LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, welcomes the recently updated interventional procedures guidance for sutureless aortic valve replacement issued by the U.K. National Institute for Health and Care Excellence (NICE), which states that sutureless aortic valve replacement is an alternative to conventional surgical aortic valve replacement. The […]

LivaNova Concludes PRELUDE Study for Transcatheter Mitral Valve Replacement System

LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology company, today announced the conclusion of the PRELUDE feasibility study for its Caisson Transcatheter Mitral Valve Replacement (TMVR) system. The PRELUDE first-in-human study evaluated the Company’s TMVR system to treat moderate to severe mitral regurgitation (MR) using a transseptal approach. This […]

LivaNova Receives FDA Clearance and Completes First Implant for its MEMO 4D Semi-rigid Mitral Annuloplasty Ring

LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it received FDA 510(k) clearance for its MEMO 4D® semi-rigid mitral annuloplasty ring and confirmed the first implantation of the device. MEMO 4D, LivaNova’s next-generation of the MEMO device family, now offers a broader range of […]

LivaNova Welcomes William Kozy to Board of Directors

LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today announced that William A. Kozy, retired Executive Vice President and Chief Operating Officer at Becton, Dickinson and Company (“BD”), was elected by the Company’s shareholders to its board of directors during its June 12 […]

LivaNova’s Perceval Sutureless Aortic Heart Valve Approved in Japan

LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced that Japan’s Ministry of Health, Labour and Welfare has approved the Company’s Perceval® sutureless aortic heart valve to treat aortic valve disease. “With this approval for Perceval, an innovative and trusted valve platform, we are able […]

LivaNova to Present at the Jefferies and Goldman Sachs Conferences

LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced company executives will present at two upcoming healthcare conferences. Chief Executive Officer Damien McDonald and Chief Financial Officer Thad Huston will participate in the Jefferies 2018 Global Healthcare Conference on Wednesday, June 6 in New […]

LivaNova Reports First Quarter 2018 Results

LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2018. For the first quarter of 2018, worldwide sales from continuing operations were $250.4 million, an increase of 10.4 percent on a reported basis and an increase […]